Shares of Fortress Biotech Inc. (NASDAQ:FBIO) were up 3.8% during trading on Friday . The company traded as high as $3.03 and last traded at $3.01, with a volume of 71,442 shares changing hands. The stock had previously closed at $2.90.

Separately, FBR & Co reaffirmed an “outperform” rating and set a $7.00 price target on shares of Fortress Biotech in a research report on Wednesday, April 6th.

The stock has a 50-day moving average price of $2.77 and a 200-day moving average price of $2.95. The company’s market cap is $146.04 million.

Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter. Equities analysts forecast that Fortress Biotech Inc. will post ($1.23) earnings per share for the current fiscal year.

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.